Shamik Bhadra, MD
Nephrology · Montebello
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 27 years
- Graduated 1999
Offices
1 location · L A County Nephrology Associates A Medical Corporation · 11 clinicians in this group
Hospitals listed: 052725 · 552585 · 552641 · 552667 · 752578 · Adventist Health White Memorial · Community Hospital of Huntington Park · East Los Angeles Doctors Hospital · Greater El Monte Community Hospital · Los Angeles Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhadra’s office at (323) 726-3868 to ask if they take your plan before you enroll.
California Medical Board record
Licence A124360 · Current
Licensed to practise in California · since 2013 · expires 2028-06-30 · University of Pune, Armed Forces Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health White MemorialLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.165, Oct 2024 – Sep 2025
- Community Hospital of Huntington ParkHuntington Park, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Pipeline Health, which runs 7 hospitals in 3 statesPatients rate it 2 of 5 · 55% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- East Los Angeles Doctors HospitalLos Angeles, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Pipeline Health, which runs 7 hospitals in 3 statesPatients rate it 1 of 5 · 50% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Greater El Monte Community HospitalSouth El Monte, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
- Los Angeles Community HospitalLos Angeles, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prospect Medical Holdings, which runs 13 hospitals in 4 statesPatients rate it 1 of 5 · 43% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.35 to 0.99), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health White Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 5 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.29) · 473 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.95 (0.58 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.08 (101.25 to 214.92) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.9 · 163 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 157 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 2,433 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,215 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,320 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.84 (0.46 to 5.23) · 632 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.96 (2.37 to 19.55) · 186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.48 to 9.73) · 166 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.45 (0 to 1.22) · 2,746 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 207 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.403 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.034 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.673 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.803 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.392 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 257 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 517 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -34.6 · 74 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -21.5 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4 · 208 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 497 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 218 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9 to 16.4) · 199 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 51 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,008 patients answered, 10% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Community Hospital of Huntington Park
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 2 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.05 (0 to 2.13) · 95 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.46 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.8 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 72 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 435 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 910 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 901 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (0.8 to 6.02) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.58 to 4.02) · 69 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 1.44) · 722 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.861 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.28 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.9 · 217 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 62.9 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.6 · 80 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 134 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.4 · 64 cases | None | Jul 2023 – Jun 2025 |
What patients said (238 patients answered, 9% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 67% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 69% |
| Patients who gave a rating of "9" or "10" (high) | 57% |
| Staff "always" explained new medications | 60% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 55% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
See every measure and the patient survey for East Los Angeles Doctors Hospital
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 1 better, 2 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.05 (0 to 2.15) · 38 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.47 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 44 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5 · 270 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 473 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 466 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (0.83 to 6.09) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.59 to 4.06) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.51 (0 to 1.71) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.367 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 83 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -24.6 · 32 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33.3 · 44 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 69 cases | None | Jul 2023 – Jun 2025 |
What patients said (153 patients answered, 7% of those asked)
| Cleanliness | 4 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 1 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 62% |
| Doctors "always" communicated well | 61% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 74% |
| Doctors "always" explained things so they could understand | 57% |
| Doctors "always" listened carefully | 60% |
| Doctors "always" treated them with courtesy and respect | 67% |
| Patients who gave a rating of "9" or "10" (high) | 45% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 59% |
| Nurses "always" listened carefully | 60% |
| Nurses "always" treated them with courtesy and respect | 68% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 50% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 79% |
See every measure and the patient survey for Greater El Monte Community Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 3 the same, 1 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.04 (0 to 2.13) · 109 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.95 (0.49 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.9 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 170 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.8 · 392 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,005 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.96 (1.33 to 6.58) · 36 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.32 (0.59 to 4.05) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 1.46) · 857 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.419 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.866 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.025 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 62 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.7 · 179 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 219 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 44 cases | None | Jul 2023 – Jun 2025 |
What patients said (188 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 69% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 57% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 59% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Los Angeles Community Hospital
Behind the star rating — Deaths: 3 better, 2 the same, 0 worse of 5 measures. Safety: 2 better, 2 the same, 0 worse of 4 measures. Readmissions: 1 better, 4 the same, 0 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.35 to 0.99) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.04) · 617 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 159.2 (99.85 to 218.55) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 5.6 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.4 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 8.1 · 392 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 1,497 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 5,775 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,759 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.99 (0.55 to 5.43) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.14 (0.48 to 3.8) · 274 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.38 (0 to 11.33) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 36 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.68) · 5,288 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 170 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -52.5 · 135 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.2 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 489 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 156 cases | None | Jul 2023 – Jun 2025 |
What patients said (433 patients answered, 9% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 60% |
| Doctors "always" communicated well | 58% |
| Staff "always" explained | 47% |
| Yes, staff "did" give patients this information | 69% |
| Yes, staff "did" give patients information about help after discharge | 63% |
| Doctors "always" explained things so they could understand | 52% |
| Doctors "always" listened carefully | 58% |
| Doctors "always" treated them with courtesy and respect | 65% |
| Patients who gave a rating of "9" or "10" (high) | 46% |
| Staff "always" explained new medications | 62% |
| Nurses "always" explained things so they could understand | 56% |
| Nurses "always" listened carefully | 55% |
| Nurses "always" treated them with courtesy and respect | 69% |
| "Always" quiet at night | 31% |
| "YES", patients would definitely recommend the hospital | 43% |
| Staff "always" explained possible side effects | 32% |
| Yes, staff "did" give patients information about possible symptoms | 76% |
Original Medicare doctor bills
$228,619
Medicare paid this office $228,619 for 513 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 284 | $87,616 | $97 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 99 | $51,994 | $290 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 168 | $26,190 | $142 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 49 | $16,293 | $247 |
| Critical care, first 30-74 minutes | 30 | $8,899 | $168 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 284 | $87,616 | $97 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 99 | $51,994 | $290 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 168 | $26,190 | $142 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 49 | $16,293 | $247 |
| Critical care, first 30-74 minutes | 30 | $8,899 | $168 |
| Return visit (30+ min) | 43 | $6,690 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $5,760 | $63 |
| Long return visit (40+ min) | 18 | $4,907 | $140 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $2,651 | $53 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 44 | $1,087 | $13 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $1,044 | $42 |
Who their Medicare patients are
513 Original Medicare patients in 2024. Average age 71 · Under 65 25% · 85 and older 14% · Women 45% · Also on Medicaid 92% · Health risk score 6.34. Sicker patients than 9 in 10 peers; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 75% · Heart failure 65% · Coronary heart disease 53% · Depression 44% · COPD 41% · Dementia 39% · Atrial fibrillation 34% · Stroke 28% · Cancer 10%.
The office billed $602,023, Medicare allowed $294,426 and paid $228,619; for 1,857 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 513 | 1,857 | 71 | 6.34 | $602,023 | $228,619 |
| 2023 | 492 | 1,604 | 71 | 6.37 | $564,856 | $223,233 |
| 2022 | 446 | 1,305 | 70 | 6.55 | $438,450 | $174,787 |
| 2021 | 453 | 1,320 | 68 | 6.18 | $477,447 | $191,369 |
| 2020 | 536 | 1,822 | 70 | 6.45 | $553,787 | $217,599 |
| 2019 | 579 | 1,754 | 70 | 6.76 | $528,563 | $206,618 |
| 2018 | 573 | 1,936 | 70 | 6.23 | $591,689 | $225,296 |
| 2017 | 480 | 2,030 | 70 | 6.64 | $695,578 | $220,022 |
| 2016 | 472 | 2,135 | 70 | 6.22 | $762,586 | $238,963 |
| 2015 | 414 | 2,197 | 69 | 6.44 | $705,429 | $227,812 |
| 2014 | 339 | 1,275 | 68 | 6.00 | $412,416 | $144,162 |
| 2013 | 139 | 461 | 70 | 5.15 | $66,275 | $33,079 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 275 | $83,408 | $101 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 105 | $64,820 | $301 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 162 | $26,233 | $145 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 37 | $10,403 | $254 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $7,191 | $67 |
| Return visit (30+ min) | 43 | $6,582 | $77 |
| Critical care, first 30-74 minutes | 17 | $3,980 | $181 |
| Long return visit (40+ min) | 18 | $2,771 | $99 |
| Hemodialysis procedure with physician evaluation | 13 | $777 | $60 |
2022: 7 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 107 | $52,604 | $308 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 201 | $47,178 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 153 | $27,232 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $10,433 | $59 |
| Return visit (30+ min) | 38 | $9,106 | $96 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $6,736 | $259 |
| Hemodialysis procedure with physician evaluation | 16 | $1,138 | $60 |
2021: 7 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 120 | $74,855 | $308 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 194 | $50,111 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $24,814 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $9,048 | $61 |
| Return visit (30+ min) | 26 | $6,460 | $101 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $6,163 | $247 |
| Short return visit (20+ min) | 24 | $1,415 | $54 |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 228 | $60,891 | $90 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 100 | $60,526 | $238 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 204 | $38,472 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 189 | $30,491 | $63 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 33 | $8,436 | $206 |
| Return visit (30+ min) | 19 | $2,037 | $70 |
| Short return visit (20+ min) | 23 | $866 | $33 |
| Hemodialysis procedure with physician evaluation | 13 | $836 | $64 |
2019: 8 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 105 | $59,958 | $244 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 205 | $43,743 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 218 | $41,214 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 216 | $30,404 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | $6,044 | $208 |
| Return visit (30+ min) | 23 | $3,624 | $81 |
| Short return visit (20+ min) | 34 | $2,623 | $57 |
| Hemodialysis procedure with physician evaluation | 28 | $1,832 | $63 |
2018: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 96 | $77,997 | $243 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 223 | $43,460 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 269 | $41,865 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 171 | $34,343 | $88 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 26 | $6,552 | $205 |
| Short return visit (20+ min) | 46 | $3,555 | $58 |
| Return visit (30+ min) | 22 | $3,014 | $84 |
| Dialysis procedure including 1 evaluation | 12 | $3,009 | $73 |
| Hemodialysis procedure with physician evaluation | 29 | $2,346 | $62 |
2017: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 331 | $75,215 | $61 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 73 | $70,367 | $242 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 202 | $38,407 | $172 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 41 | $12,290 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $9,937 | $89 |
| Return visit (30+ min) | 18 | $2,368 | $74 |
| Dialysis procedure including 1 evaluation | 12 | $1,833 | $73 |
| Hemodialysis procedure with physician evaluation | 16 | $1,040 | $61 |
2016: 8 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 68 | $82,600 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 326 | $70,598 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 226 | $43,805 | $170 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 52 | $18,178 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $9,303 | $86 |
| Dialysis procedure including 1 evaluation | 11 | $2,501 | $74 |
| Hemodialysis procedure with physician evaluation | 16 | $1,353 | $62 |
| Return visit (30+ min) | 11 | $1,233 | $77 |
2015: 7 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 60 | $100,886 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 314 | $63,005 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 148 | $29,150 | $172 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 34 | $16,558 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $11,159 | $89 |
| Dialysis procedure including 1 evaluation | 14 | $3,594 | $73 |
| Hemodialysis procedure with physician evaluation | 19 | $1,413 | $61 |
2014: 8 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 92 | $69,235 | $240 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 175 | $30,922 | $60 |
| Hemodialysis procedure with physician evaluation | 68 | $12,626 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,769 | $169 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $7,189 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $6,523 | $86 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $4,255 | $203 |
| Return visit (30+ min) | 21 | $1,856 | $81 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 84 | $12,066 | $58 |
| Hemodialysis procedure with physician evaluation | 55 | $7,041 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,993 | $111 |
| New patient visit (45+ min) | 21 | $2,787 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,441 | $84 |
| Return visit (30+ min) | 12 | $1,359 | $91 |
Medicaid work
$88,996 in 2024
Medicaid paid $88,996 for 2,204 billed services this clinician did in 2024, up to 59 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,186 | $34,005 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 197 | $29,924 |
| 1ST HOSP IP/OBS HIGH 75 | 215 | $11,498 |
| Return visit (30+ min) | 251 | $9,060 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 16 | $1,916 |
| Long return visit (40+ min) | 44 | $1,831 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 295 | $761 |
| 2024 | 2,204 | 7 | 59 | $88,996 |
| 2023 | 2,530 | 7 | 70 | $138,496 |
| 2022 | 1,749 | 6 | 49 | $103,821 |
| 2021 | 1,695 | 6 | 41 | $93,860 |
| 2020 | 1,874 | 6 | 51 | $89,487 |
| 2019 | 2,421 | 7 | 53 | $92,073 |
| 2018 | 3,496 | 9 | 50 | $116,967 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,430 | $51,955 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 236 | $46,427 |
| 1ST HOSP IP/OBS HIGH 75 | 289 | $18,477 |
| Return visit (30+ min) | 335 | $10,144 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 142 | $4,401 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 28 | $4,027 |
| Long return visit (40+ min) | 70 | $3,065 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 214 | $42,970 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 802 | $30,559 |
| 1ST HOSP IP/OBS HIGH 75 | 219 | $15,319 |
| Return visit (30+ min) | 337 | $8,788 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 156 | $5,075 |
| New patient visit (45+ min) | 21 | $1,110 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 222 | $40,619 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 845 | $27,927 |
| 1ST HOSP IP/OBS HIGH 75 | 221 | $14,233 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 229 | $5,865 |
| Return visit (30+ min) | 166 | $4,935 |
| Short return visit (20+ min) | 12 | $281 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 201 | $33,885 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 874 | $26,281 |
| 1ST HOSP IP/OBS HIGH 75 | 266 | $16,578 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 452 | $10,005 |
| Return visit (30+ min) | 46 | $1,967 |
| Short return visit (20+ min) | 35 | $772 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 213 | $27,143 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 879 | $26,458 |
| 1ST HOSP IP/OBS HIGH 75 | 336 | $18,235 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 639 | $16,438 |
| Return visit (30+ min) | 61 | $2,104 |
| Injection, doxercalciferol, 1 mcg | 262 | $1,176 |
| Short return visit (20+ min) | 31 | $518 |
2018
| Service | 25 | $35,101 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 307 | $30,328 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 526 | $11,802 |
| 1ST HOSP IP/OBS HIGH 75 | 263 | $11,181 |
| Injection, epoetin alfa, 100 units (for esrd on dialysis) | 150 | $9,672 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 662 | $9,016 |
| Injection, doxercalciferol, 1 mcg | 1,327 | $6,467 |
| Iron sucrose injection | 169 | $2,175 |
| Short return visit (20+ min) | 67 | $1,224 |
Drugs they prescribed that Part D paid
$617,354
Pharmacies billed $617,354 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,955) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
2,281 generic and 649 brand-name prescriptions · $617,354 in drug cost · 67 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Velphoro | 67 | $191,817 | $2,863 |
| Lokelma | 155 | $124,919 | $806 |
| Veltassa | 67 | $69,708 | $1,040 |
| Kerendia | 89 | $57,929 | $651 |
| Auryxia | 22 | $31,388 | $1,427 |
See all 50 drugs
| Velphoro | 67 | $191,817 | $2,863 |
| Lokelma | 155 | $124,919 | $806 |
| Veltassa | 67 | $69,708 | $1,040 |
| Kerendia | 89 | $57,929 | $651 |
| Auryxia | 22 | $31,388 | $1,427 |
| Epogen | 53 | $26,826 | $506 |
| Januvia | 30 | $21,563 | $719 |
| Farxiga | 38 | $21,247 | $559 |
| Sevelamer Carbonate | 67 | $12,195 | $182 |
| Jardiance | 11 | $6,381 | $580 |
| Dapagliflozin | 13 | $6,359 | $489 |
| Prosol | 17 | $2,414 | $142 |
| Nifedipine Er | 95 | $1,605 | $17 |
| Losartan | 330 | $1,601 | $5 |
| Metolazone | 48 | $1,464 | $30 |
| Gentamicin Sulfate | 30 | $1,375 | $46 |
| Midodrine | 13 | $1,210 | $93 |
| Calcitriol | 95 | $1,074 | $11 |
| Chlorthalidone | 90 | $870 | $10 |
| Furosemide | 243 | $793 | $3 |
| Benazepril | 79 | $713 | $9 |
| Metoprolol | 90 | $654 | $7 |
| Lisinopril | 188 | $588 | $3 |
| Bumetanide | 43 | $560 | $13 |
| Potassium Chloride | 29 | $493 | $17 |
| Potassium Citrate Er | 20 | $469 | $23 |
| Vitamin D2 | 41 | $452 | $11 |
| Enalapril Maleate | 43 | $413 | $10 |
| Olmesartan Medoxomil | 19 | $411 | $22 |
| Carvedilol | 88 | $387 | $4 |
| Hydralazine | 16 | $270 | $17 |
| Allopurinol | 54 | $265 | $5 |
| Amlodipine Besylate | 76 | $213 | $3 |
| Hydroxychloroquine Sulfate | 11 | $202 | $18 |
| Tamsulosin | 25 | $165 | $7 |
| Atorvastatin | 38 | $156 | $4 |
| Levothyroxine | 11 | $126 | $11 |
| Valsartan | 12 | $121 | $10 |
| Pantoprazole | 22 | $84 | $4 |
| Simvastatin | 25 | $83 | $3 |
| Metformin | 18 | $66 | $4 |
| Metoclopramide | 18 | $65 | $4 |
| Prednisone | 19 | $62 | $3 |
| Glipizide | 11 | $48 | $4 |
| Ciprofloxacin | 25 | $42 | $2 |
| Spironolactone | 12 | $34 | $3 |
| Cephalexin | 11 | $32 | $3 |
| Hydrochlorothiazide | 29 | $26 | $1 |
| Glimepiride | 12 | $26 | $2 |
| Omeprazole | 12 | $23 | $2 |
Year by year
| 2024 | 2,955 | 302 | 0% (0) | 22% | $617,354 |
| 2023 | 2,499 | 249 | None | 25% | $586,740 |
| 2022 | 2,218 | 197 | 0% (0) | 24% | $511,207 |
| 2021 | 1,682 | 168 | None | 24% | $423,496 |
| 2020 | 1,679 | 184 | None | 26% | $288,801 |
| 2019 | 1,304 | 179 | 1% (16) | None | $522,922 |
| 2018 | 993 | 127 | 1% (12) | 26% | $105,594 |
| 2017 | 844 | 117 | None | 35% | $351,392 |
| 2016 | 765 | 103 | 2% (16) | None | $192,325 |
| 2015 | 734 | 110 | 2% (11) | None | $257,281 |
| 2014 | 1,030 | 195 | 1% (13) | None | $227,917 |
| 2013 | 304 | 97 | None | None | $39,172 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Velphoro | 44 | $152,540 | $3,467 |
| Lokelma | 146 | $118,904 | $814 |
| Veltassa | 61 | $58,195 | $954 |
| Kerendia | 68 | $48,300 | $710 |
| Epogen | 48 | $27,023 | $563 |
| Januvia | 39 | $22,871 | $586 |
| Auryxia | 14 | $22,234 | $1,588 |
| Sevelamer | 30 | $22,159 | $739 |
| Farxiga | 33 | $20,190 | $612 |
| Sevelamer Carbonate | 22 | $11,575 | $526 |
| Novolog | 12 | $10,832 | $903 |
| Prosol | 39 | $5,955 | $153 |
| Basaglar Kwikpen U-100 | 12 | $4,233 | $353 |
| Losartan | 276 | $3,390 | $12 |
| Metolazone | 45 | $2,377 | $53 |
| Calcitriol | 87 | $1,717 | $20 |
| Lisinopril | 161 | $1,434 | $9 |
| Furosemide | 214 | $1,404 | $7 |
| Chlorthalidone | 86 | $1,399 | $16 |
| Nifedipine Er | 47 | $1,253 | $27 |
| Metoprolol | 63 | $1,061 | $17 |
| Comfort Ez Pen Needle | 11 | $1,005 | $91 |
| Midodrine | 16 | $986 | $62 |
| Gentamicin Sulfate | 15 | $976 | $65 |
| Benazepril | 62 | $942 | $15 |
| Amlodipine Besylate | 63 | $899 | $14 |
| Potassium Citrate Er | 19 | $857 | $45 |
| Carvedilol | 63 | $836 | $13 |
| Potassium Chloride | 32 | $689 | $22 |
| Tamsulosin | 35 | $547 | $16 |
| Atorvastatin | 26 | $525 | $20 |
| Metoclopramide | 33 | $435 | $13 |
| Allopurinol | 53 | $379 | $7 |
| Bumetanide | 14 | $365 | $26 |
| Pantoprazole | 19 | $355 | $19 |
| Famotidine | 12 | $354 | $30 |
| Glipizide Er | 22 | $333 | $15 |
| Simvastatin | 24 | $300 | $13 |
| Omeprazole | 20 | $271 | $14 |
| Enalapril Maleate | 21 | $267 | $13 |
| Irbesartan | 17 | $244 | $14 |
| Metformin | 12 | $190 | $16 |
| Ciprofloxacin | 36 | $150 | $4 |
| Hydralazine | 16 | $119 | $7 |
| Prednisone | 13 | $80 | $6 |
| Amlodipine Besylate-Benazepril | 12 | $63 | $5 |
| Metoprolol | 11 | $60 | $5 |
| Hydrochlorothiazide | 18 | $47 | $3 |
| Easy-Touch Insulin | 13 | $13 | $1 |
2022: 48 drugs
| Velphoro | 61 | $162,901 | $2,671 |
| Lokelma | 109 | $82,908 | $761 |
| Veltassa | 65 | $61,659 | $949 |
| Auryxia | 19 | $26,257 | $1,382 |
| Januvia | 46 | $25,595 | $556 |
| Sevelamer | 34 | $16,430 | $483 |
| Kerendia | 26 | $15,300 | $588 |
| Epogen | 29 | $14,347 | $495 |
| Sevelamer Carbonate | 28 | $10,994 | $393 |
| Novolog | 12 | $10,709 | $892 |
| Prosol | 44 | $6,934 | $158 |
| Clinolipid | 13 | $4,188 | $322 |
| Metolazone | 43 | $2,913 | $68 |
| Losartan | 164 | $2,232 | $14 |
| Lisinopril | 202 | $2,226 | $11 |
| Potassium Citrate Er | 22 | $1,554 | $71 |
| Calcitriol | 78 | $1,459 | $19 |
| Furosemide | 220 | $1,274 | $6 |
| Gentamicin Sulfate | 22 | $1,130 | $51 |
| Comfort Ez Pen Needle | 12 | $1,098 | $91 |
| Chlorthalidone | 47 | $1,033 | $22 |
| Midodrine | 15 | $887 | $59 |
| Amlodipine Besylate | 93 | $802 | $9 |
| Carvedilol | 64 | $645 | $10 |
| Metoprolol | 44 | $638 | $14 |
| Nifedipine Er | 15 | $453 | $30 |
| Tamsulosin | 31 | $400 | $13 |
| Benazepril | 30 | $377 | $13 |
| Potassium Chloride | 24 | $362 | $15 |
| Simvastatin | 31 | $341 | $11 |
| Atorvastatin | 29 | $270 | $9 |
| Glipizide Er | 18 | $254 | $14 |
| Famotidine | 11 | $224 | $20 |
| Enalapril Maleate | 17 | $220 | $13 |
| Allopurinol | 31 | $219 | $7 |
| Levothyroxine | 12 | $196 | $16 |
| Pantoprazole | 15 | $179 | $12 |
| Bumetanide | 17 | $176 | $10 |
| Glimepiride | 15 | $170 | $11 |
| Ciprofloxacin | 30 | $124 | $4 |
| Hydrochlorothiazide | 21 | $111 | $5 |
| Cephalexin | 14 | $97 | $7 |
| Metoclopramide | 17 | $97 | $6 |
| Metformin | 12 | $68 | $6 |
| Omeprazole | 14 | $40 | $3 |
| Metoprolol | 11 | $36 | $3 |
| Insulin | 25 | $33 | $1 |
| Easy-Touch Insulin | 13 | $16 | $1 |
2021: 43 drugs
| Velphoro | 63 | $181,301 | $2,878 |
| Lokelma | 69 | $52,165 | $756 |
| Veltassa | 47 | $44,314 | $943 |
| Januvia | 40 | $24,997 | $625 |
| Sevelamer Carbonate | 60 | $24,959 | $416 |
| Epogen | 31 | $18,006 | $581 |
| Auryxia | 19 | $16,549 | $871 |
| Sevelamer | 14 | $9,205 | $657 |
| Prosol | 28 | $3,851 | $138 |
| Gentamicin Sulfate | 36 | $2,221 | $62 |
| Metolazone | 15 | $1,327 | $88 |
| Calcitriol | 54 | $1,271 | $24 |
| Losartan | 94 | $1,195 | $13 |
| Chlorthalidone | 43 | $1,095 | $25 |
| Potassium Citrate Er | 12 | $1,033 | $86 |
| Furosemide | 166 | $962 | $6 |
| Lisinopril | 148 | $897 | $6 |
| Calcium Acetate | 13 | $848 | $65 |
| Irbesartan | 13 | $651 | $50 |
| Potassium Chloride | 34 | $582 | $17 |
| Nifedipine Er | 13 | $477 | $37 |
| Carvedilol | 41 | $471 | $11 |
| Labetalol | 12 | $391 | $33 |
| Amlodipine Besylate | 72 | $354 | $5 |
| Atorvastatin | 18 | $264 | $15 |
| Glipizide Er | 15 | $261 | $17 |
| Lactulose | 11 | $243 | $22 |
| Tamsulosin | 19 | $235 | $12 |
| Metoprolol | 22 | $218 | $10 |
| Hydralazine | 11 | $216 | $20 |
| Simvastatin | 36 | $214 | $6 |
| Allopurinol | 18 | $187 | $10 |
| Levothyroxine | 17 | $184 | $11 |
| Glipizide | 22 | $171 | $8 |
| Glimepiride | 11 | $150 | $14 |
| Metoclopramide | 24 | $133 | $6 |
| Ciprofloxacin | 16 | $116 | $7 |
| Omeprazole | 27 | $111 | $4 |
| Benazepril | 18 | $99 | $5 |
| Metformin Hcl Er | 11 | $65 | $6 |
| Metformin | 13 | $63 | $5 |
| Pantoprazole | 14 | $53 | $4 |
| Insulin | 28 | $41 | $1 |
2020: 34 drugs
| Velphoro | 55 | $143,860 | $2,616 |
| Prosol | 147 | $26,419 | $180 |
| Lokelma | 36 | $24,252 | $674 |
| Sevelamer Carbonate | 36 | $16,195 | $450 |
| Epogen | 18 | $10,845 | $602 |
| Januvia | 13 | $8,184 | $630 |
| Clinisol | 26 | $4,379 | $168 |
| Clinolipid | 12 | $3,049 | $254 |
| Calcitriol | 64 | $2,512 | $39 |
| Calcium Acetate | 28 | $2,305 | $82 |
| Chlorthalidone | 73 | $1,801 | $25 |
| Gentamicin Sulfate | 24 | $1,253 | $52 |
| Potassium Citrate Er | 13 | $1,178 | $91 |
| Losartan | 94 | $988 | $11 |
| Furosemide | 158 | $816 | $5 |
| Lisinopril | 161 | $814 | $5 |
| Metoprolol | 38 | $794 | $21 |
| Irbesartan | 18 | $765 | $43 |
| Potassium Chloride | 26 | $748 | $29 |
| Amlodipine Besylate | 59 | $335 | $6 |
| Carvedilol | 25 | $288 | $12 |
| Pantoprazole | 28 | $238 | $9 |
| Hydralazine | 17 | $235 | $14 |
| Tamsulosin | 11 | $205 | $19 |
| Levothyroxine | 16 | $199 | $12 |
| Omeprazole | 26 | $183 | $7 |
| Benazepril | 32 | $182 | $6 |
| Lovastatin | 26 | $172 | $7 |
| Atorvastatin | 15 | $150 | $10 |
| Prednisone | 14 | $79 | $6 |
| Simvastatin | 14 | $78 | $6 |
| Ciprofloxacin | 17 | $55 | $3 |
| Hydrochlorothiazide | 11 | $51 | $5 |
| Glipizide | 18 | $43 | $2 |
2019: 31 drugs
| Velphoro | 17 | $32,364 | $1,904 |
| Renvela | 12 | $16,989 | $1,416 |
| Sevelamer Carbonate | 42 | $15,966 | $380 |
| Januvia | 20 | $9,768 | $488 |
| Clinisol | 56 | $8,153 | $146 |
| Prosol | 42 | $7,513 | $179 |
| Chlorthalidone | 67 | $1,465 | $22 |
| Gentamicin Sulfate | 22 | $1,415 | $64 |
| Calcium Acetate | 12 | $913 | $76 |
| Lisinopril | 142 | $794 | $6 |
| Furosemide | 151 | $749 | $5 |
| Calcitriol | 26 | $699 | $27 |
| Metoprolol | 19 | $654 | $34 |
| Losartan | 67 | $644 | $10 |
| Potassium Chloride | 19 | $618 | $33 |
| Atorvastatin | 18 | $334 | $19 |
| Amlodipine Besylate | 45 | $305 | $7 |
| Hydralazine | 17 | $282 | $17 |
| Allopurinol | 15 | $206 | $14 |
| Omeprazole | 16 | $204 | $13 |
| Carvedilol | 21 | $189 | $9 |
| Benazepril | 26 | $163 | $6 |
| Pantoprazole | 20 | $133 | $7 |
| Metoprolol | 15 | $107 | $7 |
| Lovastatin | 15 | $92 | $6 |
| Hydrochlorothiazide | 11 | $80 | $7 |
| Dextrose in Water | 31 | $78 | $3 |
| Prednisone | 14 | $71 | $5 |
| Tamsulosin | 11 | $68 | $6 |
| Glipizide | 19 | $53 | $3 |
| Ciprofloxacin | 11 | $30 | $3 |
2018: 28 drugs
| Renvela | 25 | $32,538 | $1,302 |
| Prosol | 100 | $18,012 | $180 |
| Sevelamer Carbonate | 16 | $9,590 | $599 |
| Januvia | 14 | $6,964 | $497 |
| Calcium Acetate | 19 | $1,528 | $80 |
| Chlorthalidone | 46 | $1,082 | $24 |
| Lisinopril | 99 | $493 | $5 |
| Nifedipine Er | 24 | $472 | $20 |
| Calcitriol | 18 | $439 | $24 |
| Furosemide | 76 | $304 | $4 |
| Losartan | 24 | $291 | $12 |
| Amlodipine Besylate | 34 | $286 | $8 |
| Potassium Chloride | 12 | $284 | $24 |
| Hydralazine | 19 | $176 | $9 |
| Pantoprazole | 24 | $156 | $6 |
| Omeprazole | 16 | $148 | $9 |
| Triamcinolone Acetonide | 11 | $129 | $12 |
| Dextrose in Water | 27 | $121 | $4 |
| Lovastatin | 17 | $119 | $7 |
| Carvedilol | 14 | $117 | $8 |
| Atorvastatin | 11 | $116 | $11 |
| Metoprolol | 24 | $85 | $4 |
| Benazepril | 13 | $67 | $5 |
| Metformin | 16 | $65 | $4 |
| Gabapentin | 14 | $59 | $4 |
| Glipizide | 16 | $51 | $3 |
| Simvastatin | 13 | $44 | $3 |
| Prednisone | 11 | $44 | $4 |
2017: 22 drugs
| Renvela | 40 | $58,701 | $1,468 |
| Sensipar | 53 | $56,043 | $1,057 |
| Lantus | 18 | $10,223 | $568 |
| Prosol | 31 | $7,464 | $241 |
| Humulin R | 15 | $3,073 | $205 |
| Calcium Acetate | 21 | $2,728 | $130 |
| Chlorthalidone | 49 | $1,122 | $23 |
| Gentamicin Sulfate | 11 | $618 | $56 |
| Lisinopril | 90 | $499 | $6 |
| Furosemide | 90 | $430 | $5 |
| Nifedipine Er | 22 | $319 | $15 |
| Amlodipine Besylate | 54 | $307 | $6 |
| Trueplus Insulin | 12 | $260 | $22 |
| Propranolol | 12 | $194 | $16 |
| Gabapentin | 23 | $182 | $8 |
| Losartan | 23 | $145 | $6 |
| Pantoprazole | 20 | $114 | $6 |
| Clonidine | 11 | $89 | $8 |
| Spironolactone | 12 | $88 | $7 |
| Allopurinol | 12 | $87 | $7 |
| Lovastatin | 14 | $66 | $5 |
| Metoprolol | 15 | $62 | $4 |
2016: 16 drugs
| Renvela | 44 | $79,307 | $1,802 |
| Sensipar | 32 | $25,180 | $787 |
| Renagel | 14 | $24,262 | $1,733 |
| Calcium Acetate | 77 | $10,254 | $133 |
| Lantus | 19 | $5,026 | $265 |
| Chlorthalidone | 30 | $779 | $26 |
| Amlodipine Besylate | 61 | $433 | $7 |
| Lisinopril | 69 | $325 | $5 |
| Carvedilol | 32 | $294 | $9 |
| Clonidine | 22 | $185 | $8 |
| Furosemide | 29 | $131 | $5 |
| Pentoxifylline | 11 | $115 | $10 |
| Benazepril | 15 | $106 | $7 |
| Gabapentin | 22 | $106 | $5 |
| Tramadol | 14 | $37 | $3 |
| Metoprolol | 12 | $33 | $3 |
2015: 22 drugs
| Renvela | 93 | $144,400 | $1,553 |
| Renagel | 20 | $43,089 | $2,154 |
| Velphoro | 11 | $22,926 | $2,084 |
| Sensipar | 33 | $22,673 | $687 |
| Lantus | 18 | $5,821 | $323 |
| Calcium Acetate | 42 | $5,087 | $121 |
| Chlorthalidone | 14 | $455 | $33 |
| Hydralazine | 14 | $388 | $28 |
| Metoprolol | 13 | $298 | $23 |
| Amlodipine Besylate | 52 | $281 | $5 |
| Tamsulosin | 14 | $263 | $19 |
| Carvedilol | 28 | $218 | $8 |
| Clonidine | 24 | $214 | $9 |
| Omeprazole | 26 | $208 | $8 |
| Warfarin | 15 | $179 | $12 |
| Lisinopril | 24 | $168 | $7 |
| Gabapentin | 26 | $165 | $6 |
| Clopidogrel | 18 | $164 | $9 |
| Benazepril | 12 | $137 | $11 |
| Metoprolol | 21 | $119 | $6 |
| Atorvastatin | 13 | $115 | $9 |
| Furosemide | 12 | $51 | $4 |
2014: 22 drugs
| Sensipar | 104 | $101,150 | $973 |
| Renvela | 65 | $72,939 | $1,122 |
| Sevelamer Carbonate | 15 | $13,383 | $892 |
| Calcium Acetate | 13 | $2,260 | $174 |
| Chlorthalidone | 90 | $1,838 | $20 |
| Metolazone | 23 | $660 | $29 |
| Calcitriol | 15 | $495 | $33 |
| Furosemide | 93 | $432 | $5 |
| Amlodipine Besylate | 45 | $382 | $8 |
| Metoprolol | 12 | $376 | $31 |
| Hydrochlorothiazide | 12 | $375 | $31 |
| Lisinopril | 78 | $374 | $5 |
| Allopurinol | 80 | $343 | $4 |
| Losartan | 32 | $304 | $10 |
| Carvedilol | 20 | $259 | $13 |
| Levofloxacin | 16 | $214 | $13 |
| Gabapentin | 13 | $161 | $12 |
| Bumetanide | 15 | $154 | $10 |
| Metoprolol | 26 | $120 | $5 |
| Benazepril | 16 | $92 | $6 |
| Spironolactone | 12 | $81 | $7 |
| Omeprazole | 14 | $72 | $5 |
2013: 8 drugs
| Renvela | 22 | $17,702 | $805 |
| Sensipar | 13 | $13,999 | $1,077 |
| Chlorthalidone | 49 | $740 | $15 |
| Amlodipine Besylate | 28 | $192 | $7 |
| Furosemide | 20 | $161 | $8 |
| Allopurinol | 29 | $151 | $5 |
| Levofloxacin | 13 | $131 | $10 |
| Lisinopril | 13 | $56 | $4 |
Money from drug and device companies
$1,661 in 2025
| 2025 | 18 | 76 | None | $1,661 |
| 2024 | 16 | 60 | None | $1,084 |
| 2023 | 16 | 60 | None | $1,119 |
| 2022 | 16 | 103 | None | $2,019 |
| 2021 | 10 | 48 | None | $1,065 |
| 2020 | 7 | 28 | None | $590 |
| 2019 | 7 | 37 | None | $899 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Akebia Therapeutics | Vafseo | $242 | 9 payments
|
| Calliditas Therapeutics US | Tarpeyo | $191 | 7 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $172 | 6 payments
|
| GlaxoSmithKline | Benlysta | $168 | 7 payments
|
| Amgen | Krystexxa | $138 | 10 payments
|
| Ardelyx | Ibsrela | $114 | 4 payments
|
See all 76 published payments
| Amgen | Meals · 2025-12-18 | Krystexxa | $7 |
| Akebia Therapeutics | Meals · 2025-12-16 | Vafseo | $30 |
| Calliditas Therapeutics US | Meals · 2025-12-10 | Tarpeyo | $24 |
| Vifor Pharma | Meals · 2025-12-08 | Veltassa | $21 |
| Scpharmaceuticals | Meals · 2025-11-13 | Furoscix | $26 |
| Akebia Therapeutics | Meals · 2025-11-12 | Vafseo | $26 |
| ANI Pharmaceuticals | Meals · 2025-11-05 | Purified Cortrophin Gel | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-04 | Farxiga | $20 |
| Novartis Pharmaceuticals | Meals · 2025-11-03 | None | $19 |
| Ardelyx | Meals · 2025-10-23 | Ibsrela | $34 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | None | $18 |
| Scpharmaceuticals | Meals · 2025-10-08 | Furoscix | $27 |
| Amgen | Meals · 2025-10-07 | Krystexxa | $2 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-02 | Jardiance | $28 |
| Amgen | Meals · 2025-09-26 | Krystexxa | $3 |
| GlaxoSmithKline | Meals · 2025-09-25 | Benlysta | $27 |
| Akebia Therapeutics | Meals · 2025-09-24 | Vafseo | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-23 | Jardiance | $27 |
| Fresenius USA Marketing | Meals · 2025-09-22 | Velphoro | $25 |
| Scpharmaceuticals | Meals · 2025-09-11 | Furoscix | $18 |
| Akebia Therapeutics | Meals · 2025-09-09 | Vafseo | $27 |
| ANI Pharmaceuticals | Meals · 2025-09-02 | Purified Cortrophin Gel | $35 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $38 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-26 | Jardiance | $27 |
| Abbott Laboratories | Meals · 2025-08-22 | Absolute Pro | $17 |
| GlaxoSmithKline | Meals · 2025-08-21 | Benlysta | $19 |
| Ardelyx | Meals · 2025-08-21 | Ibsrela | $28 |
| OPKO Pharmaceuticals | Meals · 2025-08-20 | Rayaldee | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-23 | Kerendia | $23 |
| Amgen | Meals · 2025-07-23 | Tavneos | $22 |
| Fresenius USA Marketing | Meals · 2025-07-23 | Velphoro | $24 |
| GlaxoSmithKline | Meals · 2025-07-18 | Benlysta | $28 |
| Novartis Pharmaceuticals | Meals · 2025-07-09 | None | $15 |
| Ardelyx | Meals · 2025-07-08 | Ibsrela | $28 |
| Akebia Therapeutics | Meals · 2025-07-02 | Vafseo | $18 |
| ANI Pharmaceuticals | Meals · 2025-07-01 | Purified Cortrophin Gel | $2 |
| ANI Pharmaceuticals | Meals · 2025-07-01 | Purified Cortrophin Gel | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-25 | Jardiance | $19 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-23 | Kerendia | $22 |
| Amgen | Meals · 2025-06-19 | Krystexxa | $5 |
| Ardelyx | Meals · 2025-06-19 | Ibsrela | $24 |
| Novartis Pharmaceuticals | Meals · 2025-06-16 | None | $28 |
| Travere Therapeutics | Meals · 2025-06-11 | None | $0 |
| Travere Therapeutics | Meals · 2025-06-11 | None | $4 |
| Travere Therapeutics | Meals · 2025-06-11 | None | $23 |
| ANI Pharmaceuticals | Meals · 2025-06-05 | Purified Cortrophin Gel | $32 |
| Calliditas Therapeutics US | Meals · 2025-06-03 | Tarpeyo | $23 |
| Akebia Therapeutics | Meals · 2025-05-31 | Vafseo | $27 |
| Akebia Therapeutics | Meals · 2025-05-27 | Vafseo | $30 |
| Calliditas Therapeutics US | Meals · 2025-05-21 | Tarpeyo | $24 |
| Amgen | Meals · 2025-05-16 | Tavneos | $21 |
| ANI Pharmaceuticals | Meals · 2025-05-09 | Purified Cortrophin Gel | $35 |
| Novo Nordisk | Meals · 2025-05-08 | Ozempic | $22 |
| Travere Therapeutics | Meals · 2025-05-07 | None | $1 |
| Travere Therapeutics | Meals · 2025-05-07 | None | $26 |
| Fresenius USA Marketing | Meals · 2025-05-06 | Velphoro | $25 |
| Travere Therapeutics | Meals · 2025-04-30 | None | $24 |
| Travere Therapeutics | Meals · 2025-04-29 | None | $2 |
| GlaxoSmithKline | Meals · 2025-04-16 | Benlysta | $31 |
| Calliditas Therapeutics US | Meals · 2025-04-15 | Tarpeyo | $29 |
| Amgen | Meals · 2025-04-08 | Krystexxa | $11 |
| Calliditas Therapeutics US | Meals · 2025-03-27 | Tarpeyo | $26 |
| Amgen | Meals · 2025-03-17 | Krystexxa | $24 |
| Akebia Therapeutics | Meals · 2025-03-12 | Vafseo | $30 |
| GlaxoSmithKline | Meals · 2025-03-10 | Benlysta | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-03 | Lokelma | $16 |
| Fresenius USA Marketing | Meals · 2025-02-26 | Velphoro | $23 |
| Calliditas Therapeutics US | Meals · 2025-02-25 | Tarpeyo | $27 |
| Amgen | Meals · 2025-02-19 | Tavneos | $22 |
| Amgen | Meals · 2025-02-18 | Krystexxa | $21 |
| GlaxoSmithKline | Meals · 2025-02-12 | Benlysta | $1 |
| GlaxoSmithKline | Meals · 2025-02-12 | Benlysta | $31 |
| Otsuka America Pharmaceutical | Meals · 2025-01-15 | Jynarque | $25 |
| Akebia Therapeutics | Meals · 2025-01-14 | Vafseo | $28 |
| Travere Therapeutics | Meals · 2025-01-07 | None | $0 |
| Travere Therapeutics | Meals · 2025-01-07 | None | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,084
| AstraZeneca Pharmaceuticals LP | Farxiga | $258 | 7 payments
|
| Amgen | Aranesp | $183 | 10 payments
|
| Travere Therapeutics | None | $106 | 7 payments
|
| Aurinia Pharma U.S. | Lupkynis | $85 | 3 payments
|
| GlaxoSmithKline | Benlysta | $67 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $58 | 2 payments
|
| Akebia Therapeutics | Auryxia | $57 | 2 payments
|
| Novartis Pharmaceuticals | None | $43 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $41 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $39 | 2 payments
|
| Ardelyx | Ibsrela | $30 | 1 payment
|
| Vifor Pharma | Veltassa | $29 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $24 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $22 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $21 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $21 | 1 payment
|
2023: $1,119
| Akebia Therapeutics | Auryxia | $174 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $166 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $143 | 6 payments
|
| Otsuka America Pharmaceutical | Jynarque | $96 | 4 payments
|
| Calliditas Therapeutics US | Tarpeyo | $93 | 5 payments
|
| Amgen | Tavneos | $70 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $62 | 3 payments
|
| GlaxoSmithKline | Benlysta | $48 | 2 payments
|
| Travere Therapeutics | None | $46 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $45 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $42 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $35 | 1 payment
|
| Lilly USA | Mounjaro | $33 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $23 | 1 payment
|
| Novo Nordisk | Rybelsus | $23 | 1 payment
|
| Vifor Pharma | Veltassa | $21 | 1 payment
|
2022: $2,019
| Fresenius USA Marketing | Velphoro | $323 | 22 payments
|
| GlaxoSmithKline | Benlysta | $309 | 9 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $276 | 15 payments
|
| Akebia Therapeutics | Auryxia | $195 | 9 payments
|
| Otsuka America Pharmaceutical | Jynarque | $167 | 7 payments
|
| Horizon Therapeutics plc | Krystexxa | $155 | 12 payments
|
| Calliditas Therapeutics US | Tarpeyo | $153 | 7 payments
|
| OPKO Pharmaceuticals | Rayaldee | $73 | 4 payments
|
| Novo Nordisk | Rybelsus | $69 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $69 | 3 payments
|
| Vifor Pharma | Veltassa | $69 | 4 payments
|
| Amgen | Parsabiv | $52 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $45 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $23 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $23 | 1 payment
|
| Travere Therapeutics | None | $21 | 1 payment
|
2021: $1,065
| Horizon Therapeutics plc | Krystexxa | $306 | 16 payments
|
| GlaxoSmithKline | Benlysta | $220 | 9 payments
|
| Akebia Therapeutics | Auryxia | $147 | 8 payments
|
| Vifor Pharma | Veltassa | $122 | 5 payments
|
| Otsuka America Pharmaceutical | Jynarque | $119 | 3 payments
|
| Amgen | Parsabiv | $53 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $39 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $23 | 1 payment
|
| Genzyme | None | $20 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $15 | 1 payment
|
2020: $590
| AstraZeneca Pharmaceuticals LP | Lokelma | $202 | 11 payments
|
| Relypsa | Veltassa | $115 | 5 payments
|
| Akebia Therapeutics | Auryxia | $112 | 5 payments
|
| Mallinckrodt Hospital Products | Acthar | $64 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $43 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $36 | 2 payments
|
| GlaxoSmithKline | Benlysta | $19 | 1 payment
|
2019: $899
| Amgen | Parsabiv | $273 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $172 | 5 payments
|
| Fresenius USA Marketing | Velphoro | $138 | 10 payments
|
| Otsuka America Pharmaceutical | Jynarque | $132 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $102 | 3 payments
|
| Relypsa | Veltassa | $44 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $38 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GlaxoSmithKline, LLC. · A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P · 2019 | Their institution | $46,149 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P · 2020 | Their institution | $37,281 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P · 2021 | Their institution | $26,222 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P · 2022 | Their institution | $18,855 |
| Travere Therapeutics, Inc. · 021igan17001 · 2021 | Their institution | $17,807 |
| Travere Therapeutics, Inc. · 021igan17001 · 2020 | Their institution | $15,226 |
| Retrophin, Inc. · 021igan17001 · 2019 | Their institution | $6,077 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P · 2023 | Their institution | $4,533 |
Checkups this office reported
13 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 90.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 17%That's few of the people this applied to. | 856 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 64%That's more than half. | 224 |
| Checked for fall riskOlder patients screened for fall risk | 0%That's few of the people this applied to. | 255 |
| Colon cancer screeningEligible adults who got a colon cancer test | 10%That's few of the people this applied to. | 266 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 2%That's few of the people this applied to. | 181 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 44%That's less than half. Better on this measure. | 181 |
| Medications listed in the chartVisits where the current medication list was documented | 61%That's more than half. | 1,752 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 81%That's most of the people this applied to. | 195 |
See the other 5 measures
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 90%That's most of the people this applied to. | 515 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 265 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 32% | 332 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 83%That's most of the people this applied to. | 207 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 45%That's less than half. | 421 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Depression screening
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Implementation of medication management practice improvements
- Improved the patient portal
- Lets patients read their visit notes
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports to a public-health or clinical registry
- Uses standard treatment protocols
- Exempt from immunization registry reporting
Professional record
- NPI
- 1114910908
- Licence
- CA A124360California A124360: Current · expires 2028-06-30
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- AZ 949662, CA WA124360
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 2149 E Warner Rd Ste 102, Tempe, AZ, 85284
- NPI first listed
- 2005-08-26
- NPI last updated
- 2019-08-22
This is when the NPI record was last certified, not a medical board exam.